Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Current Opinion in Immunology
|
April 26, 2011
Dengue vaccines: progress and challenges
Beth-Ann G Coller, David E Clements
Journal of Virology
|
February 2, 2024
Translational success of fundamental virology: a VSV-vectored Ebola vaccine
Elizabeth M Anderson, Beth-Ann G Coller
Idrugs : the Investigational Drugs Journal
|
December 15, 2010
Advances in flavivirus vaccine development
Beth-Ann G Coller, David E Clements, Timothy Martyak, et al.
Vaccine
|
July 23, 2011
The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease
Beth-Ann G Coller, David E Clements, Andrew J Bett, et al.
Vaccines
|
December 23, 2020
Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
Joan G Tell, Beth-Ann G Coller, Sheri A Dubey, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
December 3, 2014
Advances in the understanding, management, and prevention of dengue
Laura L Hermann, Swati B Gupta, Susan B Manoff, et al.
Vaccine
|
July 7, 2015
Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates
Dhanasekaran Govindarajan, Steven Meschino, Liming Guan, et al.
Viruses
|
March 27, 2025
Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model
Sandra L Bixler, Amy C Shurtleff, Melek M E Sunay, et al.
The American Journal of Tropical Medicine and Hygiene
|
May 21, 2026
A Phase 1, Open Label, Safety Study of HBV-002 (West Nile Recombinant Subunit Vaccine) in Healthy Adults
Beth-Ann G Coller, David E Clements, Michele Yelmene, et al.
Vaccine
|
October 8, 2022
Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials
Jakub K Simon, Stephen B Kennedy, Barbara E Mahon, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Current Opinion in Immunology
|
April 26, 2011
Dengue vaccines: progress and challenges
Beth-Ann G Coller, David E Clements
Journal of Virology
|
February 2, 2024
Translational success of fundamental virology: a VSV-vectored Ebola vaccine
Elizabeth M Anderson, Beth-Ann G Coller
Idrugs : the Investigational Drugs Journal
|
December 15, 2010
Advances in flavivirus vaccine development
Beth-Ann G Coller, David E Clements, Timothy Martyak, et al.
Vaccine
|
July 23, 2011
The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease
Beth-Ann G Coller, David E Clements, Andrew J Bett, et al.
Vaccines
|
December 23, 2020
Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
Joan G Tell, Beth-Ann G Coller, Sheri A Dubey, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
December 3, 2014
Advances in the understanding, management, and prevention of dengue
Laura L Hermann, Swati B Gupta, Susan B Manoff, et al.
Vaccine
|
July 7, 2015
Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates
Dhanasekaran Govindarajan, Steven Meschino, Liming Guan, et al.
Viruses
|
March 27, 2025
Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model
Sandra L Bixler, Amy C Shurtleff, Melek M E Sunay, et al.
The American Journal of Tropical Medicine and Hygiene
|
May 21, 2026
A Phase 1, Open Label, Safety Study of HBV-002 (West Nile Recombinant Subunit Vaccine) in Healthy Adults
Beth-Ann G Coller, David E Clements, Michele Yelmene, et al.
Vaccine
|
October 8, 2022
Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials
Jakub K Simon, Stephen B Kennedy, Barbara E Mahon, et al.
Page
of 3